Results 141 to 150 of about 1,204,560 (279)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Impact of resection for ovarian metastases from colorectal cancer and clinicopathologic analysis: A multicenter retrospective study in Japan

Annals of Gastroenterological Surgery
Aim The aim of this study was to clarify the significance of resection of ovarian metastases from colorectal cancer and to identify the clinicopathologic characteristics.
Hiroyasu Kagawa, Yusuke Kinugasa, Tomohiro Yamaguchi, Masayuki Ohue, Kazushige Kawai, Junichiro Hiro, Seiichi Shinji, Hiroaki Nozawa, Yasumitsu Hirano, Koji Komori, Yasumasa Takii, Takeshi Suto, Shunsuke Tsukamoto, Yoshito Akagi, Heita Ozawa, Yuji Toiyama, Kazuhito Minami, Tomoharu Shimizu, Kay Uehara, Kazuhiro Sakamoto, Keita Mori, Kenichi Sugihara, Yoichi Ajioka   +22 more
doaj   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Correction: Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44 + cancer stem cells to 5 azacytidine in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, 2023
Xiaomei Gao, Yuanyuan Sheng, Jing Yang, Chaoqun Wang, Rui Zhang, Ying Zhu, Ze Zhang, Kaili Zhang, Shican Yan, Haoting Sun, Jinwang Wei, Xuan Wang, Xinxin Yu, Yu Zhang, Qin Luo, Yan Zheng, Peng Qiao, Yue Zhao, Qiongzhu Dong, Lunxiu Qin   +19 more
doaj   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

NOL7 facilitates melanoma progression and metastasis

Signal Transduction and Targeted Therapy, 2021
Yumei Li, Chunlian Zhong, Jie Wang, Fan Chen, Weiyu Shen, Bifei Li, Ning Zheng, Yusheng Lu, Vladimir L. Katanaev, Lee Jia   +9 more
doaj   +1 more source

Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine releaseResearch in context

EBioMedicine, 2019
Background: Treatment multiple tumors by immune therapy can be achieved by mobilizing both innate and adaptive immunity. The programmed death ligand 1 (PD-L1; or CD274, B7-H1) is a critical “don't find me” signal to the adaptive immune system.
Shu Lian, Ruizhi Xie, Yuying Ye, Xiaodong Xie, Shuhui Li, Yusheng Lu, Bifei Li, Yunlong Cheng, Vladimir L. Katanaev, Lee Jia   +9 more
doaj  

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Metastasis [PDF]

, 2011
openaire   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source